Itraconazole is best absorbed with a fatty meal; therefore, avoid taking it on an empty stomach. Limit alcohol intake because both alcohol and itraconazole can stress the liver.
Having a pacemaker does not automatically contraindicate itraconazole, but if you have underlying heart disease or a history of arrhythmias, discuss the medication with your cardiologist due to the risk of QT prolongation.
Even after completing a 12-week course for onychomycosis, the nail may take several months to grow out completely. Visible improvement usually appears within 6-12 weeks after therapy ends.
Yes. In the UK, itraconazole capsules are typically white to off-white and may bear imprint codes such as “I-100” or “I-200” denoting the strength. In other countries, colour and imprint can differ.
Itraconazole is not a controlled substance and is not screened for in standard workplace drug tests. However, occupational health assessments may request a medication history.
You may carry a prescription copy and the original pharmacy label. Some countries require a medical certificate for prescription medicines, so check the destination’s regulations before travel.
Itraconazole does not directly affect blood glucose. Nonetheless, liver impairment can alter metabolism of some oral hypoglycaemic agents, so routine monitoring is advisable.
Take the missed dose as soon as you remember, provided it is more than 12 hours before the next scheduled dose. Otherwise, skip it and continue with the regular timing.
Itraconazole has broader activity against dermatophytes and some moulds (e.g., Aspergillus) compared with fluconazole, which is more effective against Candida species. Choice depends on the specific fungus identified.
No. Itraconazole capsules should be stored at room temperature, away from excessive heat and moisture. Refrigeration is unnecessary and may affect capsule integrity.
Itraconazole belongs to the azole class of antifungal agents and is prescribed for a range of systemic and topical fungal infections. It is available in capsule form in strengths of 100 mg and 200 mg and is classified as a prescription-only medicine (POM) in the United Kingdom under the regulation of the Medicines and Healthcare products Regulatory Agency (MHRA).
Itraconazole exerts its antifungal effect by inhibiting the fungal enzyme lanosterol 14-α-demethylase, a member of the cytochrome P450 family. This enzyme is essential for converting lanosterol into ergosterol, the primary sterol that maintains fungal cell-membrane integrity. By blocking ergosterol synthesis, itraconazole destabilises the membrane, leading to leakage of cellular contents and inhibition of fungal growth.
Key pharmacological points:
Itraconazole is approved in the UK for the following indications:
These uses are supported by clinical trial data and are reflected in the product’s Summary of Product Characteristics (SmPC) approved by the MHRA.
Some clinicians employ itraconazole off-label for conditions such as chronic pulmonary aspergillosis or refractory dermatophytosis, where evidence from observational studies suggests benefit. These uses are not approved by the MHRA and should only be considered after a thorough risk-benefit assessment by a specialist.
Disclaimer: Off-label use requires medical supervision and individualized risk assessment.
If you fall into any of these categories, discuss alternatives with your prescriber.
These effects are usually mild and transient. If they persist or worsen, contact your healthcare provider.
Immediately seek medical attention if you experience chest pain, severe abdominal pain, jaundice, or marked swelling.
Itraconazole is a potent inhibitor of CYP3A4 and can raise plasma concentrations of many co-administered drugs.
| Interaction Type | Examples | Clinical Impact | ||-|--| | Major | Statins (lovastatin, simvastatin), certain benzodiazepines (midazolam), ergot derivatives, pimozide | Increased risk of myopathy, sedation, or severe hypotension. | | Moderate | Calcium channel blockers (verapamil), certain antihistamines, some antiretrovirals (e.g., ritonavir) | Requires dose adjustment or close monitoring. | | Inducers that lower itraconazole levels | Rifampicin, carbamazepine, phenytoin | May lead to therapeutic failure; avoid co-administration. |
Because interaction profiles are extensive, always provide a full medication list (prescription, over-the-counter, supplements, herbal products) to your prescriber or pharmacist.
Note: The exact regimen must be individualized by a healthcare professional. Do not alter the dose without medical advice.
If you forget a dose, take it as soon as you remember provided it is more than 12 hours before the next scheduled dose. Do not double-dose.
Symptoms may include severe nausea, vomiting, abdominal pain, and liver dysfunction. Seek emergency medical care; treatment is supportive. Activated charcoal may be considered if presentation is early.
Some fungal infections require a gradual taper to avoid rebound growth, especially in chronic pulmonary aspergillosis. Follow your prescriber’s instructions for stopping therapy.
This article provides educational information about itraconazole and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
